BAVARIAN NORDIC WKN: 917165 ISIN: DK0015998017 Kürzel: 0DPB Forum: Aktien Thema: Hauptdiskussion

.

Gibt bestimmt einige Gewinnmitnahmen und Rücksetzer morgen

🤣

du bist ja noch schlimmer als lauterbach

Steht jetzt bereits bei 38 Euro.....Morgen 100 Prozent, meine Meinung

Im Ami Forum geht die Post ab. Die Konkurrenz Aktie war 45 Plus gestiegen. Nachbörslich nochmal über 20 Prozent...

Werd mich morgen auch einkaufen, glaube das ganze wird schneller als uns lieb ist zur nächsten Pandemie...

Da werden sicher noch Folgeaufträge kommen für SIGA

And from an availability perspective, SIGA announced on May 12, 2022, that the U.S. Department of Defense (DoD) awarded a contract to SIGA for the procurement of up to approximately $7.5 million of oral TPOXX, of which approximately $3.6 million of oral TPOXX targeted for delivery in 2022.

Also kauft die USA lieber von Bavarian, statt von Siga?

Biden: U.S. exploring monkeypox vaccines; ‘everybody’ should be concerned On Wednesday, Bavarian Nordic, the Copenhagen-based company that developed the smallpox vaccine licensed for use against monkeypox in the United States, said the U.S. government had exercised its options under an agreement with the company to “supply a freeze-dried version of JYNNEOS® smallpox vaccine, thus allowing for the first doses of this version to be manufactured and invoiced in 2023 and 2024.” The order of new doses of the vaccine, which has a longer shelf life, is worth $119 million, Bavarian Nordic said in a news release. Under its agreement with the company, the U.S. Biomedical Advanced Research and Development Authority can still exercise options worth $180 million for about 13 million freeze-dried doses of the smallpox vaccine in the future. A Health and Human Services spokesperson told Axios that the purchase was not a direct response to the infections but said the doses could be used to treat monkeypox. Separately, Bavarian Nordic said it had “secured a contract with an undisclosed European country to supply its IMVANEX® smallpox vaccine in response to new cases of monkeypox evolving during May 2022.” Imvanex, as the Jynneos vaccine is known in Europe, is licensed there only for the treatment of smallpox, but it has been used “off-label” in previous monkeypox incidents. At least two European countries have moved to stockpile vaccines in a possible effort to get ahead of the spread. British Health Secretary Sajid Javid confirmed Friday that the United Kingdom — where the WHO says 21 to 30 monkeypox infections have been reported — has “procured further doses of vaccines that are effective against Monkeypox.” https://www.washingtonpost.com/politics/2022/05/22/biden-monkeypox-vaccines-outbreak/

Hättest du das bei Biontech nicht auch gedacht? ;-) ich bin zu 100% sicher, dass die 100€ kommen, noch diese Woche!